ANI PHARMACEUTICALS, INC (ANIP) FY2026 Q2 P&L / Income Statement

ANI PHARMACEUTICALS, INC (ANIP) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net Revenues

266,044,000 US dollars

Cost of revenue (calculated)

100,158,000 US dollars

Gross profit (calculated)

165,886,000 US dollars

Operating expenses (calculated)

125,426,000 US dollars

Operating income

40,460,000 US dollars

Other income (expense), net (calculated)

negative 3,363,000 US dollars

Income Before Income Tax Expense

37,097,000 US dollars

Income tax expense

12,386,000 US dollars

Net Income

24,711,000 US dollars

Generic pharmaceutical products

99,051,000 US dollars

Other generic revenues

1,605,000 US dollars

Brands

11,813,000 US dollars

Brand royalties and other revenues

17,731,000 US dollars

Cortrophin Gel

117,126,000 US dollars

ILUVIEN and YUTIQ

18,718,000 US dollars

Cost of sales (excluding depreciation and amortization)

100,158,000 US dollars

Research and development

14,747,000 US dollars

Selling, general, and administrative

91,661,000 US dollars

Depreciation and amortization

19,640,000 US dollars

Contingent consideration fair value adjustment

negative 622,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.